Diabetes mellitus (DM) is a common disease in dogs and a cause of significant patient morbidity as well as emotional and financial stress to pet owners. In this study, investigators will examine the effect of fenofibrate on alleviating some of the complications of DM. Fenofibrate is a drug known to decrease blood lipid levels that has also shown promise in laboratory settings to decrease other consequences of DM such as gut barrier dysfunction, systemic inflammation and pancreatitis. Investigators hypothesize that fenofibrate treatment in spontaneous canine DM will reduce systemic inflammation and decrease serum pancreatic lipase activity (a marker of pancreatic inflammation), and positively alter lipoprotein profiles without affecting blood sugar (glycemic) control. The results of this study will be used to design a larger long-term longitudinal clinical trial which will evaluate risk-reduction of pancreatitis and other DM complications by fenofibrate in dogs.